Business
Placing to Raise £534,375
Placing to Raise £534,375.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n\n28 November 2023\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION. \nHemogenyx Pharmaceuticals plc\n(\"Hemogenyx Pharmaceuticals\" or the \"Company\") \nPlacing to Raise £534,375\n \nHemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully raised £534,375 (before expenses) through the allotment and issue of 22,500,000 new ordinary shares at 2.375 pence per share (the \"Placing\", \"Placing Shares\"). The Placing was oversubscribed and conducted on behalf of the Company by its corporate broker, Peterhouse Capital Limited.\n \nThe net proceeds from the Placing will be used to facilitate progression of the Company's Chimeric Antigen Receptor (\"CAR\") T-cells (\"HEMO-CAR-T\") for the treatment of acute myeloid leukaemia (\"AML\"). Specifically, and as outlined by the Company in its announcement of 15 November 2023, this fundraise will help the Company to accelerate the completion of work set out in the plan presented and agreed to by the FDA and to re-submit the Investigational New Drug (\"IND\") application for the HEMO-CAR-T product. The funds will also enable the Company, in view of recently announced successes, to provide modest additional resources to the development of its CBR platform.\n \nAn application is being made to the London Stock Exchange Main Market and admission of the Placing Shares to trading is expected on or around 4 December 2023 (\"Admission\"). The Placing Shares will rank pari passu w...